文献速递前列腺癌

帕利泊芬血管靶向光动力疗法治疗低危前列腺癌的中期肿瘤学结局

Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.
PubMed 文献 · J Urol · 2017-03-18

本中心前瞻性评估82例低危前列腺癌患者接受帕利泊芬血管靶向光动力疗法后的中期肿瘤学结局,中位随访68个月。中位无进展生存期为86个月(95%CI 82-90),治疗后6个月前列腺特异性抗原中位下降41%并保持稳定,115个受治疗叶中94个(82%)达到无临床显著癌,20例(24%)接受根治性治疗。

要点

  • 82例低危前列腺癌患者接受帕利泊芬血管靶向光动力疗法,中位随访68个月(范围6-89)。
  • 中位无进展生存期86个月(95%CI 82-90),中位前列腺特异性抗原6个月下降41%(p<0.001)并保持稳定。
  • 115个治疗叶中94个(82%)无临床显著癌,20例(24%)接受根治性治疗(前列腺癌根治术18例、近距离放疗2例)。

核心结论

  • 帕利泊芬血管靶向光动力疗法治疗低危前列腺癌在治疗叶中达到82%的无临床显著癌率,中位随访68个月时76%的患者避免了根治性治疗,但需更长期随访以确定远期结局。

研究设计与样本

  • 前瞻性评估本中心所有接受血管靶向光动力疗法治疗的低危前列腺癌患者,每6个月随访,治疗后6个月或出现生物学或临床进展时行前列腺活检。
  • 共82例男性接受治疗,中位随访68个月(范围6-89个月)。
  • 主要终点为无进展生存期,次要终点为治疗叶无临床显著癌、根治性治疗及前列腺特异性抗原变化率。

主要发现

  • 中位无进展生存期为86个月(95%CI 82-90)。
  • 治疗后6个月前列腺特异性抗原中位显著下降41%(p<0.001),随访期间保持稳定。
  • 共治疗115个叶,94个(82%)达到无临床显著癌。
  • 82例患者中20例(24%)接受根治性治疗,包括前列腺癌根治术18例和近距离放疗2例,中位时间22个月(范围6-86个月)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 研究局限性包括单臂设计、样本量小及中期随访。
  • 结论指出需更长期随访以确定远期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the midterm oncologic outcomes of vascular targeted photodynamic therapy with padeliporfin for low risk prostate cancer treatment. MATERIALS AND METHODS: We prospectively assessed all patients treated with vascular targeted photodynamic therapy for low risk prostate cancer at our center. Patients were followed every 6 months. All patients underwent prostate biopsies 6 months after treatment or when there was biological or clinical progression. The primary end point was progression-free survival. Secondary end points were absent clinically significant cancer in the treated lobes, radical therapy and the prostate specific antigen rate. Variables were compared with the chi-square, Mann-Whitney or Wilcoxon test. Progression-free survival is reported with Kaplan-Meier curves. RESULTS: A total of 82 men were treated with vascular targeted photodynamic therapy. Median followup was 68 months (range 6 to 89). Median progression-free survival was 86 months (95% CI 82-90). Median prostate specific antigen decreased significantly by 41% 6 months after treatment and it remained stable during followup (p <0.001). A total of 115 lobes were treated and absent clinically significant cancer was achieved in 94 (82%). Of the 82 patients 20 (24%) underwent radical therapy, including radical prostatectomy in 18 and brachytherapy in 2, at a median of 22 months (range 6 to 86). Study limitations include a single arm design, small population size and midterm followup. CONCLUSIONS: Padeliporfin vascular targeted photodynamic therapy for low risk prostate cancer achieved an 82% rate of absent clinically significant cancer in treated lobes and 76% of patients avoided radical therapy at a median followup of 68 months. However, longer followup is required to determine long-term outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lebdai S, Bigot P, Leroux PA, et al. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes. J Urol. 2017. PMID: 28322857. doi:10.1016/j.juro.2017.03.119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。